These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Excitement mounts for first disease-modifying cystic fibrosis drugs. Opar A Nat Rev Drug Discov; 2011 Jul; 10(7):479-80. PubMed ID: 21720393 [No Abstract] [Full Text] [Related]
4. FDA deems in vitro data on mutations sufficient to expand cystic fibrosis drug label. Ratner M Nat Biotechnol; 2017 Jul; 35(7):606. PubMed ID: 28700545 [No Abstract] [Full Text] [Related]
5. Personalized medicine. New cystic fibrosis drug offers hope, at a price. Kaiser J Science; 2012 Feb; 335(6069):645. PubMed ID: 22323790 [No Abstract] [Full Text] [Related]
6. False dawn for cystic fibrosis disease modifiers? Holmes D Nat Rev Drug Discov; 2014 Oct; 13(10):713-4. PubMed ID: 25270946 [No Abstract] [Full Text] [Related]
7. Ivacaftor, vismodegib, and ingenol mebutate. Hussar DA; Eckel SP J Am Pharm Assoc (2003); 2012; 52(3):418-22. PubMed ID: 22618984 [No Abstract] [Full Text] [Related]
8. Ivacaftor (Kalydeco) for cystic fibrosis. Med Lett Drugs Ther; 2012 Apr; 54(1388):29-30. PubMed ID: 22499233 [No Abstract] [Full Text] [Related]
9. Targeting the basic defect in cystic fibrosis. Welsh MJ N Engl J Med; 2010 Nov; 363(21):2056-7. PubMed ID: 21083391 [No Abstract] [Full Text] [Related]